Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RAF1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Kinase | RAF1 WT / Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RAF1 Products |
| Gene Delivery | RAF1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View RAF1 Products |
| Benchmark Ab | Anti-RAF1 Antibody Recombinant positive control for western blot/ELISA. |
View RAF1 Products |
| Validator | RAF1 siRNA Set For knockdown verification and pathway analysis. |
View RAF1 Products |
| Related Target A | BRAF Dimerization partner and alternative pathway node. |
View BRAF Products |
| Related Target B | KRAS Upstream activator driving RAF1 dependency. |
View KRAS Products |
| Related Target C | MEK1 Downstream effector for pathway inhibition assays. |
View MEK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Activity Validation | Sequence Verified, High Purity (>95%) recombinant kinase domains for reliable biochemical screening. |
| Isoform Selectivity (BRAF vs CRAF) | Homolog panel proteins strictly verified by mass spec and sequence analysis. |
| Lack of Controls | Clinical Benchmark Antibodies included for reference standard signaling assays. |
| False Positives in Profiling | Validated siRNA included for specificity checks and genetic validation. |
Live RAF1/c-RAF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAF1 therapeutics is intensifying, with major players shifting focus from traditional mono-isoform inhibitors to Pan-RAF inhibitors and PROTAC degraders. As first-generation BRAF therapies encounter resistance via paradoxical RAF1 activation, the next wave of R&D is targeting complete RAF signal blockade and synergistic combinations with KRAS or MEK inhibitors to shut down MAPK-driven solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Pan-RAF) | Novartis, Day One Biopharmaceuticals | Solid Tumors, Melanoma | Selectivity Assay (Need High-Purity BRAF/CRAF Proteins) |
| PROTAC / Degrader | Arvinas, Kymera | Refractory NSCLC | Degradation Assay (Need Lentivirus for Stable Cell Lines) |
| Combination (MEK/KRAS) | Mirati, Amgen | KRAS-Mutant Cancers | Pathway Inhibition (Need sequence-verified effector proteins) |